A randomized, double blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 4, 1996, Pages 323-328

  Harman, Glenn S ^a   Omura, George A ^b   Ryan, Kevin ^c   Hainsworth, John D ^d   Cramer, Michael B ^e   Hahne, William F ^e  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DAVID GRANT MEDICAL CENTER   (United States)

^d CENTENNIAL MEDICAL CENTER   (United States)

^e Marion Merrell Dow Inc   (United States)

Author keywords

5 HT3 antagonist; Antiemetic; Dolasetron

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; PROPORTIONAL HAZARDS MODELS; QUINOLIZINES; SEROTONIN ANTAGONISTS; UNITED STATES; VOMITING;

EID: 0029683291     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050490     Document Type: Article

References (22)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42: 551
2. 3) receptor antagonist (MDL 73.147EF) in patients receiving high dose cisplatin chemotherapy (abstract). Proc Am Soc Clin Oncol 11 : 395
3. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 219 : 9
4. Boxenbaum H, Gillespie T, Heck K, Hahne W (1992) Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13 : 693
5. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17 : 97
6. 3 receptor antagonist (abstract). Br J Pharmacol [Suppl] 107 : 449P
7. Galvan M, Gittos MW, Fatmi M (1993) Dolasetron. Drugs Future 18 : 506
8. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329 : 1790
9. Heck K, Holmes GB, Adams MA, Hunt TL, Hahne W (1992) A double-blind, placebo-controlled, dose-rising tolerance study of intravenous MDL 73,147EF in normal volunteers (abstract). Clin Pharmacol Ther 51 : 186
10. 3 antagonists. Support Care Cancer 2 : 286
11. 3 antagonist dolasetron in patients receiving moderately emetogenic chemotherapy (abstract). Proc Am Soc Clin Oncol 13 : 463
12. Hunt TL, Cramer M, Christy-Bittel J, Shah A, Meyerson LJ, Benedict CR, Hahne WF (1996) Multiple dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy 16 : 253
13. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35 : 705
14. Kasimis B, Tapazoglou E, Schulman P, Howard L, Gramer E, Cramer M, Hahne W (1994) A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy (abstract). Proc Am Soc Clin Oncol 13 : 446
15. 3 antagonist in 41 patients requiring intravenous chemotherapy (abstract). Proc Am Soc Clin Oncol 10 : 337
16. Kirchner V, Aapro M, Alberto P, O'Grady P, Busch B, Boyce M (1993) Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 4 : 481
17. Lee CR, Plosker GL, McTavish D (1993) Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 46 : 925
18. Merrouche Y, Catimel G, Rebattu P, Dumortier A, Guastalla JP, O'Grady P, Clavel M (1994) A phase I antiemetic study of MDL 73.147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 5 : 549
19. 3 receptors. Drug Dev Res 28 : 87
20. Milne RJ, Heel RC (1991) Ondansetron. Therapeutic use as an antiemetic. Drugs 41 : 574
21. Plezia P, Modiano M, Alberts D, Bertoli L, Yielding A, Einsberg P, Khojasteh A, Gandara D, Heck K, Hahne W (1992) A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73,147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol 11 : 407
22. Plosker GL, Goa KL (1991) Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42 : 805